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Abstract
Introduction During pregnancy the mammary epithelial
compartment undergoes extreme proliferation and
differentiation, facilitated by stem/progenitor cells. Mouse
mammary epithelium in nonpregnant mice contains long label-
retaining epithelial cells (LREC) that divide asymmetrically and
retain their template DNA strands. The role of LREC during
alveogenesis has not been determined.
Methods We performed immunohistochemistry and
autoradiography on murine mammary glands that had been
labeled with 5-bromodeoxyuridine (5BrdU) during allometric
ductal growth to investigate the co-expression of DNA label
retention and estrogen receptor-α or progesterone receptor
during pregnancy. A second DNA label ([3H]-thymidine) was
administered during pregnancy to identify label-retaining cells
(LRC), which subsequently enter the cell cycle. Use of this
methodology allowed us to investigate the co-localization of
5BrdU with smooth muscle actin, CD31, cytokeratin, and
desmin in periductal or peri-acinar LRC in mammary tissue from
pregnant mice subsequent to a long chase period in order to
identify LRC.
Results Estrogen receptor-α positive and progesterone
receptor positive cells represented approximately 30% to 40%
of the LREC, which is under 1.0% of the epithelial
subpopulation. Pregnancy altered the percentage of LREC
expressing estrogen receptor-α. LRC situated in periductal or
peri-acinar positions throughout the gland do not express
epithelial, endothelial, or myoepithelial markers, and these
undefined LRCs persist throughout pregnancy. Additionally,
new cycling LREC ([3H]-thymidine retaining) appear during
alveologenesis, and LRC found in other tissue types (for
example, endothelium and nerve) within the mammary fat pad
become double labeled during pregnancy, which indicates that
they may also divide asymmetrically.
Conclusions Our findings support the premise that there is a
subpopulation of LREC in the mouse mammary gland that
persists during alveologenesis. These cells react to hormonal
cues during pregnancy and enter the cell cycle while continuing
to retain, selectively, their original template DNA. In addition,
nonepithelial LRC are found in periductal or peri-acinar
positions. These LRC also enter the cell cycle during pregnancy.
During alveologenesis, newly created label-retaining ([3H]-
thymidine) epithelial cells appear within the expanding alveoli
and continue to cycle and retain their original template DNA
([3H]-thymidine) strands, as determined by a second pulse of
5BrdU.
Introduction
In 1975, Cairns [1] postulated that dividing adult somatic stem
cells protected themselves from mutation and cancer risk by
segregating their template DNA strands. This property of
selective DNA segregation was shown to occur both in vivo
and in vitro in a variety of cell and tissue types [2-8]. In the
mouse mammary gland, label-retaining epithelial cells (LREC)
in the ducts divide asymmetrically and retain their template
DNA strands [6]. In addition, more than 80% of these LREC
remain in the cell cycle dividing actively (as indicated by their
incorporation of a second DNA label after a 48-hour pulse),
and subsequently – upon chase – bestow the newly labeled
DNA strands upon their progeny during asymmetric cell divi-
sions [6]. Ductal morphogenesis occurs between weeks 3
and 10 of age in the mouse, during which the mammary gland
is rapidly proliferating and differentiating [9]. Mammary
5BrdU: 5-bromodeoxyuridine; ER: estrogen receptor; LRC: label-retaining cells; LREC: label-retaining epithelial cells; PR: progesterone receptor; 
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epithelial stem cells contribute to this development of the
mammary gland by asymmetric division, generating both
transit-amplifying and progenitor cells that subsequently divide
by symmetric division, resulting in mammary stem cell expan-
sion. It is commonly believed that in the mature mouse the
mammary epithelium exists in a state of relative proliferative
quiescence, with the exception of short bursts during hormo-
nal stimulation manifesting as the estrus cycle, until the onset
of pregnancy [10,11]. Recent studies have indicated that con-
siderable cellular turnover occurs in mammary epithelium [12-
14]. Tissue homeostasis is maintained during this period by
stem/progenitor cells positioned throughout the mammary
ductal system.
Undifferentiated mammary stem/progenitor cells are found
microscopically, based on morphologic characteristics in rats
and mice, in suprabasal positions between the luminal and
myoepithelial cell layers [15]. The presence of these cells with
similar characteristics has also been confirmed in human mam-
mary glands [16,17]. These morphologically undifferentiated
epithelial cells persist in immortalized, hyperplastic mammary
tissue but are absent from growth senescent populations [18].
These studies provided additional evidence for mammary stem
cells that reside among the epithelial components of the gland
(for review [19]).
The importance of estrogen-mediated and progesterone-
mediated proliferation in normal mammary growth and devel-
opment is well documented [20]. We previously reported that
a subpopulation of LREC in the murine mammary gland is pos-
itive for estrogen receptor (ER)-α and/or progesterone recep-
tor (PR), and that the numbers of these cells were altered by
administration of various hormones (estrogen, progesterone,
and prolactin), either alone or in combination [21]. We also
communicated our findings that a number of nonepithelial
nuclear label-retaining cells (LRC) reside in periductal or basal
positions throughout the mammary gland. This report charac-
terizes these cells further by following them through preg-
nancy as well as assessing LREC for ER-α and PR expression
during early pregnancy. Furthermore, we examined developing
and expanding alveoli for the appearance of newly formed
LREC that are capable of cycling asymmetrically while retain-
ing their original [3H]-thymidine DNA label.
Materials and methods
Experimental plan
We conducted two separate procedures designed to label the
DNA of proliferating cells during the period of ductal elonga-
tion and development. In the first experiment mammary glands
were labeled by administration of 5-bromodeoxyuridine
(5BrdU; 1 mg) by intraperitoneal injection for 14 days starting
on the first day of week 4 of postnatal life. The label was
chased from the glands over a 6-week period after the final
injection to allow completion of ductal development. In the
second procedure, 5BrdU was administered for 2 consecu-
tives days, once each day, by intraperitoneal injection for 7
weeks beginning on week 4 of postnatal life and ending on
week 11. No label was administered for the next 3 weeks. This
constitutes the minimum chase period for the last 5BrdU injec-
tion of 3 weeks, the maximum chase (for the first inoculum)
being 10 weeks. In the second experiment Nu/Nu hosts were
used and WAP-Cre/Rosa26R parous fragments were placed
into cleared number 4 and 9 fat pads at age 3 weeks (2 weeks
before 5BrdU injections were started).
After the respective chase periods, the females were placed
with males and timed pregnancies were initiated by observing
the females for vaginal plugs each morning after an evening
with a male mouse. The actual interval between the final
5BrdU injection and ensuing pregnancy varied from 14 weeks
to 17 weeks for the first experiment and from 5 weeks to 9
weeks for the second. The females were divided into four
groups, depending on their stage in pregnancy. (Not all mice
were actually pregnant when they received the second DNA
label, although they were found with vaginal plugs; these mice
served as nonpregnant controls). Tissues from at least four
pregnant females were collected in each group.
Group 1 received an intraperitoneal injection of [3H]-thymidine
(50 μCu) on day 3 of pregnancy, and the mice were killed 2
hours after the injection. Group 2 received an intraperitoneal
injection of [3H]-thymidine (50 μCu) on day 4 of pregnancy
and the mice were killed 2 hours after the injection. Group 3
received an intraperitoneal injection of [3H]-thymidine (50
μCu) on day 6 of pregnancy and the mice were killed 2 hours
after the injection. Group 4 received an intraperitoneal injec-
tion of [3H]-thymidine (50 μCu) on day 4 of pregnancy, and
intraperitoneal injections of 5BrdU on days 11 and 12 of preg-
nancy. The mice of group 4 were killed 2 hours after the last
5BrdU injection on day 12 of pregnancy. Group 4 was
intended to define long label retaining ([3H]-thymidine-posi-
tive) alveolar epithelial cells that traverse the cell cycle while
retaining their original [3H]-thymidine label. Based on the pre-
vious elegant studies conducted by Traurig [22,23] and
Bresciani [11,24] to elucidate the mammary alveolar epithelial
cell cycle duration in pregnant mice, we estimate that at least
five to eight mammary epithelial cell cycles were completed in
the mammary epithelium of the pregnant mice during the 8-day
chase (days 4 to 13) after the [3H]-thymidine pulse [11].
The protocols and procedures used to perform the experi-
ments upon the animals were reviewed and approved by the
Animal Care and Use Committee at the National Cancer Insti-
tute at Frederick (MD, USA). Housing and care during the
experimental period conformed to the guidelines provided by
the US National Institutes of Health.
Autoradiography and immunochemistry
For autoradiography, 5 to 6 μm sections were cut, placed
upon slides, dewaxed, rehydrated through ethanol, and subse-Available online http://breast-cancer-research.com/content/10/5/R90
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quently dipped in Kodak NTB-2 liquid emulsion (Eastman
Kodak Company, Rochester, NY, USA) diluted 1:1 with dis-
tilled water. After drying, the slides were stored in lightproof
slide boxes at constant humidity and temperature for 20 days.
After exposure, the slides were developed in Kodak D-19,
washed in distilled water, and fixed in Kodak rapid fixer diluted
1:1 with distilled water. After staining and mounting, the slides
were observed and evaluated for autoradiographic grains and
for immunostaining. Images were recorded using Kodak digital
microscopy documentation system 290 and edited using
Adobe Photoshop 7.0 (Adobe, San Jose, CA, USA).
All autoradiographic exposures were performed after immuno-
histochemistry, the sections were deparaffinized and rehy-
drated, and the endogenous peroxidase was inactivated with
1% hydrogen peroxide in methanol for 30 minutes. Antibodies
used were anti-PR 1:75 (clone A009B; Dako USA, Carpinte-
ria, CA, USA), anti-ER-α 1:50 (clone MC-20; Santa Cruz Bio-
tech, Santa Cruz, CA, USA), anti-5BrdU 1:50 (Dako), anti-
smooth muscle actin (SMA) 1:150 (Sigma, St. Loius, MO),
anti-desmin 1:100 (The Binding Site, San Diego, CA), and
anti-CD31 1:200 (PECAM-1; Santa Cruz). Antigen retrieval
was accomplished in accordance with the directions of the
manufacturers. Negative tissue controls were included in all
immunohistochemical analyses. Vector Blue was used as the
chromagen for anti-5BdrU except for slides that received auto-
radiographic exposure, when diaminobenzidine was used.
Diaminobenzidine was used for anti-ER-α, anti-PR, anti-SMA,
and anti-desmin antibodies. Nova Red was used with anti-
CD31 antibody.
Determination of autoradiographic grain counts in epithelial
cells was done by counting the grains over at least 100 LRCs
in sections from each of the four mammary glands taken from
each experimental mouse for a total of 16 mammary glands per
experimental group. Determination of antigen expression
counts was done using similar methods. At least 500 labeled
cells were counted in each of these sections. At least 3,000
nuclei were examined in each slide. Examination of autoradio-
graphic slides from these tissues that were stained for PR and
ER-α revealed similar numbers of autoradiographic grains over
LREC nuclei.
Statistical analyses
The GraphPad Prism software package (GraphPad Software,
Inc., La Jolla, CA, USA) was used for all statistical analyses.
Data were considered significant at P < 0.05. Representative
data are presented as mean ± standard deviation.
Results
Several types of long label (5BrdU) retaining cells were
observed after the chase period and before pregnancy. These
included epithelial and myoepithelial cells, endothelial cells,
and cells within the muscle and nerves of the mammary gland.
We reported previously that a number of LRCs in the mam-
mary gland reside in periductal (outside the basement mem-
brane along a duct but not stromal fibroblasts) or peri-acinar
(outside the basement membrane surrounding a developing
acinar structure but not stromal fibroblasts) positions through-
out the murine mammary gland [21]. Additionally, we have
observed LRECs in basal epithelial positions defined as resid-
ing between luminal epithelial cells and myoepithelial cells.
In order to characterize these cells further, we collected mam-
mary glands from pregnant females that had received 5BrdU
constantly for 2 weeks during the allometric growth phase of
the mammary gland. These animals were divided into four
experimental groups (four animals/group and four glands from
each animal were examined), as outlined in the Materials and
methods section (above). Each group received a second
nuclear label, namely [3H]-thymidine, at different time points
throughout pregnancy: Group 1 at day 3, Group 2 at day 4,
and Group 3 at day 6; the mice in Group 4 received [3H]-thy-
midine at day 4 and also received additional 5BrdU at days 11
and 12, and were killed 2 hours later on pregnancy day 12.
Because the onset of pregnancy was not accomplished with
synchronicity, the chase period between the last injection of
5BrdU and the [3H]-thymidine injection received during preg-
nancy ranged from 45 to 100 days. We found LRCs (5BrdU-
positive cells) in periductal locations and in peri-acinar posi-
tions within developing alveoli in all experimental groups (Fig-
ure 1).
We next determined whether the periductal LRC and/or the
peri-acinar LRC were cycling during pregnancy. The mice in
groups 1, 2, and 3 received an injection of [3H]-thymidine 1 to
2 hours before death, whereas the mice in group 4 received
the [3H]-thymidine injection 7 to 8 days before death. Any cells
that took up the [3H]-thymidine in groups 1 to 3 are considered
to be cycling (in S-phase). A subpopulation of the 5BrdU-
retaining LRC in groups 1 to 3 was found to be in cycle (Figure
1, arrows). In the pregnant groups, the chase period for 5BrdU
exceeded 60 days after the last injection in all cases. In some
animals the chase period was greater than 80 days. Therefore,
these epithelial cells had maintained their original 5BrdU-
labeled DNA for a very long period after incorporation and
were in cycle when the pulse of [3H]-thymidine was given 1
hour before the mouse was killed. The purpose of group 4,
which received [3H]-thymidine on day 4 of pregnancy, was to
determine whether any of the [3H]-thymidine-labeled alveolar
cells would still retain this label after an 8-day chase. The mice
in group 4 received additional 5BrdU on days 11 and 12 of
pregnancy to determine whether any [3H]-thymidine-retaining
alveolar cells were still traversing the cell cycle. We know that
the S-phase of mouse mammary epithelial cells in alveoli of
pregnant or hormone-treated mice varies between 11 and 14
hours, based on work conducted by Bresciani [11,24] and
Traurig and Morgan [10,22,23]. Thus, if these cells remained
in cycle and divided with semiconservative (symmetric) DNA
kinetics, then the [3H]-thymidine would have been dispersedBreast Cancer Research    Vol 10 No 5    Booth et al.
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evenly among the resulting daughters and would be
undetectable by autoradiography. Therefore, [3H]-thymidine-
retaining cells remaining on day 12 of pregnancy were either
out of cycle during this period or were in cycle and selectively
retained their originally labeled DNA strands. 5BrdU-labeled
cells in group 4 numbered about 18% of the total alveolar pop-
ulation. This number compares very well with the observations
of Traurig [22] in the alveoli (12%) of 12-day pregnant mice
given [3H]-thymidine. [3H]-thymidine-retaining cells were
found among the epithelial alveolar cells on day 13 (7.3%).
About 6.1% of the approximately 18% 5BrdU-labeled alveolar
cells (76 double labeled of 1,250 5BrdU-positive cells) were
also positive for [3H]-thymidine (76 double labeled of 283 total
[3H]-thymidine positive), demonstrating that the tritium-retain-
ing cells were in cycle when 5BrdU was given at day 11 and/
or day 12 of pregnancy. We conclude that alveolar LREC arise
in alveoli during early pregnancy and function as alveolar cell
precursors, which continue to cycle asymmetrically and retain
Figure 1
LRC are in cycle during pregnancy LRC are in cycle during pregnancy. The nuclear label [3H]-thymidine is detected by autoradiography in sections of mammary tissue from pregnant 
mice that received 5BrdU for 2 weeks during weeks 4 and 5 of life (group 1 is day 3 of pregnancy, group 2 is day 4 of pregnancy, group 3 is day 6 
of pregnancy, and group 4 is day 12 of pregnancy). LRC in periductal and basal positions are evident in all time points evaluated. Arrows indicate 
double positive cells. Scale bars = 10 μm. 5BrdU, 5-bromodeoxyuridine; LRC, label-retaining cell.Available online http://breast-cancer-research.com/content/10/5/R90
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their originally [3H]-thymidine labeled DNA during alveolar
expansion.
LRC that express the myoepithelial marker SMA were found in
all experimental groups. These myoepithelial LRC were found
along ducts and developing acinar structures in early preg-
nancy (group 1; Figure 2a), in later pregnancy (groups 2 and
3; Figures 2b,c) and in mid-pregnancy (group 4; Figure 2d). In
late pregnant animals the majority of myoepithelial LRC were
located in acini (Figure 2d). In all groups LRC were observed
both inside the basement membrane and outside the base-
ment membrane (Figure 2, arrows). In no instance did we find
any LRC outside the basement membrane that expressed
SMA. Similar results were obtained when we stained for an
additional mesenchymal marker, namely desmin (results not
shown). Tissue sections from each group were also stained for
the epithelial markers cytokeratins. The LRC found in periduc-
tal or peri-acinar positions in all experimental groups were not
positive for cytokeratin (Figure 3, arrows). These findings indi-
cate that this subset of periductal or peri-acinar LRC do not
express either myoepithelial and mesenchymal markers (SMA
or desmin) or an epithelial marker (for instance, cytokeratin),
leading us to conclude that these cells are undefined cycling
cells.
To characterize the LRCs further, we determined whether any
expressed the endothelial marker CD31 (also known as
PECAM-1 [platelet/endothelial cell adhesion molecule 1]).
CD31 is expressed on endothelial cells, monocytes, neu-
trophils, platelets, and some T cells [25]. In none of the groups
did we find any epithelial LRC that expressed CD31 or any
periductal or peri-acinar CD31+ LRC (results not shown). We
found numerous endothelial cells in all experimental groups
that were labeled with 5BrdU, after long chase periods, which
indicates that some endothelial cells are long-label-retaining
(Figure 4). We found that some label-retaining endothelial
cells were also [3H]-thymidine labeled in pregnant females of
groups 1 to 3 that received a pulse, 1 hour before they were
killed. Therefore, some long label (5BrdU)-retaining endothe-
lial cells also entered the cell cycle and became double
labeled during early pregnancy, presumably corresponding
with increased angiogenesis. All LRC lining the blood vessels
were CD31 positive, and some were double labeled by the
second marker of DNA synthesis, [3H]-thymidine (Figure 5a).
Additional cell types within the mammary glands also incorpo-
rated 5BrdU-forming LRC. Cells within mammary nerves and
adipocytes in the fatty stroma retained 5BrdU (Figure 5 panels
b and c, respectively) and can be classified as LRC. The for-
mation of LRC is not solely a property of epithelial cells but of
all cell types (epithelial, myoepithelial, endothelial, stromal, and
neural) that develop within the mammary gland.
We did not find any instances of periductal or basal LRC
(5BrdU positive) that were ER-α positive (Figure 6a) or PR
positive (Figure 6b) at any stage during pregnancy. The same
was true for androgen receptor expression; specifically, no
periductal or basally located LRC were positive for androgen
receptor (Figure 6c). This indicates that the periductal LRC do
not express any of the three nuclear hormone receptors
investigated.
In our previous report [21] we indicated that a number of
LREC are ER-α positive and/or PR positive, and these num-
bers change in response to hormonal stimulation [21]. We
next investigated whether the hormonal fluctuations that occur
during pregnancy affect the numbers of ER-α-positive and PR-
positive LREC. We found a significant decrease in the number
of LREC that were also PR positive between group 1 (38.6 ±
8.5%) and group 2 (28.4 ± 6.6; P = 0.0446). We also noted
a decreasing trend between groups 1 and 3 (29.9 ± 3.0%),
although this was not quite statistically significant (P = 0.2;
Table 1). The decrease in the percentage of PR-positive LREC
in group 4 was statistically significant compared with all other
experimental groups. In all experimental groups we noted an
increase in the percentage of LREC (as defined by 5BrdU
retention in groups 1 to 3 and [3H]-thymidine retention in
group 4) within the PR-positive population when compared
with nonpregnant control animals (Table 2). No significant
changes were recorded in the ratio of ER-α within the LREC
population between groups 1, 2, or 3. These results match our
Figure 2
Periductal LRC are not myoepithelial cells Periductal LRC are not myoepithelial cells. Sections from all experimen-
tal groups were stained for the myoepithelial marker SMA (brown). LRC 
(blue, 5BrdU) in periductal or peri-acinar positions are not SMA positive 
(arrows). (a) Group 1. (b) Group 2 cells are endothelial except for 
arrows. (c) Group3. (d) Group 4. Scale bars = 15 μm. 5BrdU, 5-bromo-
deoxyuridine; LRC, label-retaining cell; SMC, smooth muscle actin.Breast Cancer Research    Vol 10 No 5    Booth et al.
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previous findings when we examined LREC after nulliparous
animals had received injections of estrogen, progesterone,
and prolactin for 5 days [21]. In experimental groups 1 to 3 the
percentage of LREC/PR-positive cells within the PR-positive
population remained constant but the percentage of PR-posi-
tive cells within the entire epithelial population decreased as
pregnancy progressed. This suggests that LREC/PR-positive
alveolar cells are distinct from the rest of the PR-positive cell
population. In group 4 the total number of steroid receptor
expressing cells in the entire mammary epithelium decreased
by nearly threefold (Table 2). As mentioned above, [3H]-thymi-
dine retention defines the long label retaining cells in group 4,
and 5BrdU incorporation defines the cells traversing the cell
cycle when this label was administered on days 11 and 12 of
pregnancy. Any cell that retained [3H]-thymidine (defined as
autoradiographic detection of at least four grains) was consid-
ered label retaining in this analysis. In group 4, nearly one out
of every five ER-α-positive cells or PR-positive cells were also
[3H]-thymidine retaining (Table 2). This indicates that a propor-
tion of the steroid receptor expressing cells are LREC. The
observation that the proportion of LREC also positive for these
steroid receptors remains unchanged despite the diminished
percentage of total nuclear steroid receptor expressing cells
supports the interpretation that the steroid receptor positive
LREC are distinct from the main steroid receptor positive
population.
An additional finding was that numerous ER-α-positive and
PR-positive cells incorporated [3H]-thymidine, indicating that
the nuclear steroid expressing cells are traversing the cell
cycle. We found ER-α/[3H]-thymidine and PR/[3H]-thymidine
double-positive cells in all four experimental groups (Figure 7).
Because the [3H]-thymidine was given to the animals shortly
before death in experimental groups 1 to 3, the only cells that
would incorporate the nuclear label are those cells that are in
cycle or just beginning to cycle through S-phase. The ER-α/
[3H]-thymidine and PR/[3H]-thymidine double-positive cells
found in group 4 (Figure 7, far right column) are different from
those found in groups 1 to 3 because [3H]-thymidine defines
the LRC and not 5BrdU. The [3H]-thymidine was given 8 days
Figure 3
Periductal LRC are not epithelial cells Periductal LRC are not epithelial cells. Sections from all experimental groups were stained for the epithelial markers cytokeratins (green). LRC (red, 
5BrdU) in periductal or peri-acinar positions are not cytokertin positive (arrows). Scale bars = 10 μm. 5BrdU, 5-bromodeoxyuridine; LRC, label-
retaining cell.
Figure 4
LRC in blood vessels are CD31 positive LRC in blood vessels are CD31 positive. Sections from all experimental groups were stained for the endothelial marker CD31 (brown). LRC (blue, 
5BrdU) in blood vessels are also CD31 positive. Scale bars = 10 μm. 5BrdU, 5-bromodeoxyuridine; LRC, label-retaining cell.Available online http://breast-cancer-research.com/content/10/5/R90
Page 7 of 11
(page number not for citation purposes)
before the animals were killed, indicating that one of two sce-
narios occurred. In group 4, where 5BrdU defines cells in
cycle, we found that 18% were 5BrdU positive, and of these
more than one in five were doubly labeled with [3H]-thymidine.
This demonstrates that a large proportion of the [3H]-thymi-
dine retaining cell was traversing the cell cycle when 5BrdU
was given. A small possibility is that the double-labeled cells
observed on day 4 of pregnancy represent these double-
labeled cells at day 13, but this is unlikely because the total
alveolar population has increased approximately 8-fold to 10
fold [26].
Discussion
The data presented in this study demonstrate that long label
retaining cells within the murine mammary gland comprise
numerous cell types, including undifferentiated stromal cells,
luminal epithelial cells, myoepithelial cells, and neural and
endothelial cells. We observed cycling LRC, as determined by
incorporation of the second nuclear label, both inside (epithe-
lial) and outside (nonepithelial) the basement membrane, and
these cells persisted throughout early and mid-pregnancy.
Additionally, we found that the expression patterns of ER-α
and PR in LREC are altered in response to the hormonal
changes during pregnancy.
These results are similar to our previous findings when we
examined LREC after nulliparous animals had received injec-
tions of estrogen, progesterone, and prolactin for 5 days [21].
After treatments with estrogen, progesterone, and prolactin,
we identified a significant increase in ER-α-positive LREC and
a decreasing trend in LREC that are PR positive. We con-
firmed this observation in intact pregnant females in the
present report. During pregnancy we observed a similar trend
of increasing numbers of ER-α-positive cells and a significant
decrease in PR-positive LREC in early pregnancy.
Stem cells that reside in the mammary gland are positioned in
basal and suprabasal positions in the ducts and alveoli
[15,27]. These mammary stem/progenitor cells are undifferen-
tiated pale cells that are characterized by a lack of cytoplasmic
organelles and their uncondensed chromatin. These cells have
been characterized on the basis of their size into undifferenti-
ated large light cells and small light cells (SLC). It is these cells
that enter the cell cycle when cultured as mammary explants
[28]. Additionally, these cells have been analyzed through the
different stages of mammary development and the percentage
of each morphotype calculated. These studies [15] revealed
that the percentage of SLC in the general epithelial population
did not change from puberty throughout pregnancy and into
post-lactation involution, even though the number of mammary
epithelial cells increased by 20-fold to 30-fold. This suggests
that the numbers of SLC expand and contract coordinately
with the total epithelial population, and implies that they have
an essential role to play in the maintenance and expansion of
the mammary epithelial cell population. The numbers of undif-
ferentiated large light cells in the total population was much
more variable, suggesting that they may represent a transi-
tional state in the progression of SLC progeny to fully differen-
tiated epithelial cells.
The hierarchy of stem/progenitor cells in mouse mammary tis-
sue is comprised of three types of progenitor cells [18,28-30]:
duct limited (no alveologenesis), lobule limited (no duct mor-
phogenesis), and unlimited stem/progenitor cells. Mammary
outgrowths that originate from either duct-limited or lobule-lim-
ited progenitors are comprised of myoepithelial and luminal
epithelial cells, with a population of the luminal cells express-
ing ER and/or PR [30]. Additional experiments have demon-
strated that entire mammary outgrowths are the progeny of a
single cell that gives rise to all mammary cell types [26]. After
Figure 5
LRC in nonepithelial mammary cells LRC in nonepithelial mammary cells. (a) Endothelial cells that line a 
blood vessel are BrdU positive #a fraction of those are in cycle, as 
determined by [3H]-thymidine incorporation (arrow). (b) LRC exist in a 
mammary nerve (brown, BrdU positive). (c) LRC in fatty stroma (brown, 
BrdU positive). Scale bars = 10 μm. 5BrdU, 5-bromodeoxyuridine; 
LRC, label-retaining cell.Breast Cancer Research    Vol 10 No 5    Booth et al.
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multiple transplantation generations when growth senescence
develops, the capacity to develop ducts or alveoli is lost inde-
pendently [18]. Because each progenitor type gives rise to
ER-positive and PR-positive cells, it is feasible that ER-positive
and PR-positive epithelial cells arise from distinctly different
antecedents during ductal growth and alveolar growth,
because each probably perform different functions in mam-
mary gland development and differentiation [31] (Smith GH,
Medina D, unpublished observations). ER-α-null mice do not
develop a ductal tree past the rudimentary tree present at
birth, but when wild-type epithelium is transplanted into an ER-
α-null fat pad it develops fully [32]. Our data demonstrate that
populations of ER-α-positive and/or PR-positive cells are in
cycle during pregnancy, whereas the rest of the nuclear ster-
oid receptor expressing cells are not. ER-α-positive and/or
PR-positive LREC may represent asymmetrically cycling
LREC that are functionally distinct from ER-negative/PR-neg-
ative LREC. These observations suggest that cells among the
ER-α-positive and PR-positive populations may arise from dif-
ferent antecedents and may be performing different functions
within the gland.
Nuclear label retention for extended periods in individual cells
may be explained by the presence of originally labeled cells
that went out of cycle shortly after the label was administered.
LRC may also represent cells that traverse the cell cycle very
slowly. A recent study in which mammary epithelial cells were
fluorescently sorted on the basis of proposed stem cell sur-
face marker expression (CD24 and the α6β1 integrin complex)
indicated that mouse mammary stem cells are ER-α, PR, and
erbB2 negative [33], suggesting an undifferentiated pheno-
type. Undifferentiated cells are found in basal positions
throughout the mammary gland [15], in a similar manner as for
the undefined LRC described in this report.
Partially differentiated cells are observed in rapidly proliferat-
ing pregnant tissue, [3H]-thymidine labeled cells, and repre-
sent transit-amplifying cells committed to a secretory cell fate.
We found a significant increase in the number of labeled ER-
α-positive and an increasing number of labeled PR-positive
cells (not statistically significant) in group 4 at day 12 of preg-
nancy, suggesting that the receptor-positive cells are in cycle
or recently exited the cell cycle. Because no nuclear label had
been added since day 4 of pregnancy, this indicates that some
of the cells labeled at day 4 subsequently became ER-α-posi-
Figure 6
Periductal LRC do not have nuclear hormone receptors Periductal LRC do not have nuclear hormone receptors. Sections from all experimental groups were stained for the nuclear hormone receptors (a) 
ER-α, (b) PR, or (c) AR (green). Arrows indicate that periductal LRC (red, 5BrdU) are not double positive for the receptors. Scale bars = 10 μm. AR, 
adrogen receptor; 5BrdU, 5-bromodeoxyuridine; ER, estrogen receptor; LRC, label-retaining cell; PR, progesterone receptor.Available online http://breast-cancer-research.com/content/10/5/R90
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tive and/or PR-positive, and either stopped cycling or initiated
asymmetric cellular division. Those cells that are double posi-
tive for 5BrdU and [3H]-thymidine represent the latter. It was
recently hypothesized in a human model that nuclear steroid
receptor positive cells exhibit stem cell characteristics of self-
renewal by asymmetric division to produce transit-amplifying
cells and differentiated progeny [34].
We previously reported the presence of periductal LRC that
lie outside the basement membrane [6,21]. These cells do not
cycle in mammary glands of mice treated with estrogen, estro-
gen/progesterone, or estrogen/progesterone/prolactin [6],
but we found them in cycle during early pregnancy, which sug-
gests that local signals may regulate their entry into the cell
cycle. These cells do not express an endothelial marker
(CD31), mesenchymal markers (SMA or desmin), or epithelial
markers (cytokeratins, ER-α, or PR). They continue to cycle, as
demonstrated by the uptake of [3H]-thymidine, at least 6
weeks after the final injection of 5BrdU. One possibility is that
these LRC represent future ductal branching points or alveoli
that form during pregnancy. Reversible adipocyte-to-epithe-
lium and epithelium-to-adipocyte transdifferentiation has been
demonstrated indirectly during pregnancy and involution [35].
It is known that there are three distinct types of progenitor cells
in the murine mammary gland, and these periductal LRC may
be examples of progenitor cells in a semidormant state, in
which they are only involved in maintenance until the proper
hormonal cues arise during pregnancy, at which time they ini-
tiate the formation of new ductal and lobule structure. This
observation suggests that label-retaining progenitor cells
might occupy specific microenvironmental locations.
Not only did we find numerous CD31-positive endothelial LRC
lining the blood vessels in all of the groups (Figure 4), but we
also found numerous endothelial LRC in pregnant mice that
were cycling, as determined by [3H]-thymidine uptake (Figure
5a). This observation agrees with the increase in vasculature
associated with pregnancy [36]. Proliferation and expansion of
a tissue is stem/progenitor cell dependent, suggesting that the
cycling endothelial LRC act as progenitor cells during
pregnancy.
The implication of protection from mutation during DNA repli-
cation in cells that asymmetrically divide and reduced cancer
risk was previously discussed [2]. So why then is breast can-
cer still one of the most prominent cancers in women? The
continuous rounds of cellular proliferation and apoptosis dur-
ing the menstrual cycle and any pregnancies create more pos-
sibilities for mutation during replication than most other tissues
Table 1
Percentages of receptor positive cells within the LREC 
population
Time point % ER-α positivea % PR positivea
Virgin control 30.7 ± 1.35 31.6 ± 3.1
Group 1 26.5 ± 5.3 38.6 ± 8.5
Group 2 27.9 ± 7.5 28.4 ± 6.6
Group 3 29.3 ± 8.9 29.9 ± 3.0
Group 4 27.2 ± 3.6 14.6 ± 6.5*
One thousand cells were counted in mammary gland sections 
stained for 5BrdU and ER-α or 5BrdU and PR. ([3H]-thymidine and 
steroid receptors were counted for Group 4.) Group 1 tissue was 
collected at day 3 of pregnancy, Group 2 tissue was collected at day 
4 of pregnancy, Group 3 tissue was collected at day 6 of pregnancy, 
and Group 4 tissue was collected at day 13 pregnancy after a 
second 5BrdU dose at day 4. Values are expressed as mean ± 
standard deviation. aDouble positive for 5BrdU and receptor/total 
5BrdU positive. *P < 0.05 versus all groups individually. 5BrdU, 5-
bromodeoxyuridine; ER, estrogen receptor; LREC, label-retaining 
epithelial cell; PR, progesterone receptor.
Table 2
Percentages of LREC within the receptor positive cell population
Time point % ER-α-positive 
LREC populationa
% ER-α-positive 
total populationa
Ratio of % ER-α-
positive LREC to total 
% ER-α-positive 
populationa
% PR-positive 
LREC populationa
% PR-positive 
total populationa
Ratio of PR-positive 
LREC to total PR-
positive populationa
Non-pregnant 11.4 ± 3.2 16.1 ± 2.45 11.4/16.1 = 0.7081 14.1 ± 4.1 21.9 ± 5.96 14.1/21.9 = 0.6438
Group 1 10.1 ± 2.4 20.6 ± 5.92 10.1/20.6 = 0.4903 19.3 ± 5.9 22.4 ± 4.20 19.3/22.4 = 0.8616
Group 2 12.8 ± 7.9 16.1 ± 7.74 12.8/16.1 = 0.7950 18.0 ± 7.4 19.5 ± 4.23 18.0/19.5 = 0.9424
Group 3 13.7 ± 5.3 20.1 ± 5.64 13.7/20.1 = 0.6816 18.3 ± 10.1 14.3 ± 4.92*† 18.3/14.3 = 1.2797
Group 4 18.3 ± 8.1 6.62 ± 2.17* 18.3/6.62 = 2.7644 19.3 ± 9.4 6.5 ± 1.47*† 19.3/6.5 = 2.9692
One thousand cells were counted in mammary gland sections stained for 5BrdU and ER-α or 5BrdU and PR. ([3H]-thymidine and steroid 
receptors were counted for Group 4). Group 1 tissue was collected at day 3 of pregnancy, Group 2 tissue was collected at day 4 of pregnancy, 
Group 3 tissue was collected at day 6 of pregnancy, and Group 4 tissue was collected at day 13 of pregnancy after second 5BrdU dose at day 
4. Values are expressed as mean ± standard deviation, or as %/% = ratio. aDouble positive for 5BrdU and receptor/total receptor positive. *P < 
0.05 versus virgin control; †P < 0.05 versus group 1. 5BrdU, 5-bromodeoxyuridine; ER, estrogen receptor; LREC, label-retaining epithelial cells; 
PR, progesterone receptor.Breast Cancer Research    Vol 10 No 5    Booth et al.
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and organs, where cellular turnover is less frequent.
The present findings indicate that undefined cells, committed
progenitor/transit-amplifying cells, and stem cells that take up
nuclear label during allometric growth of the mammary gland
and retain this label continue to cycle throughout pregnancy,
and that ER-α and PR expression in these cells is affected by
pregnancy.
Conclusions
We conclude that long-lived cells characterized by their pro-
pensity to retain selectively their original DNA strands persist
in adult mammary glands. This class of cells is represented in
the mammary epithelium, in mammary-associated endothe-
lium, and in neural tissue present in the fat pad. These cells are
stimulated during pregnancy to enter the cell cycle and to con-
tribute new progeny to their respective tissues through asym-
metric divisions. During the expansion of the alveolar
epithelium throughout pregnancy, new long label retaining epi-
thelial cells, including ER-α-positive and PR-positive cells,
arise among the expanding alveolar epithelium and continue to
cycle asymmetrically while maintaining their originally labeled
DNA copy. Our observations suggest that somatic cells des-
tined to proliferate extensively in tissue homeostasis and, upon
subsequent tissue expansion, undertake this role by adopting
selective segregation of their original DNA in order to facilitate
replacement or expansion of committed tissue cells that are
devoid of genomic defects due to DNA replication.
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